Invest in Smart Home Tech with Superior Patents
Invest in a hot tech start-up poised to be the next Ring Doorbell and Nest Thermostat
Continue Reading

CNTA Insider Trading (Centessa Pharmaceuticals)

Insider Ownership Percentage: 9.09%
Insider Buying (Last 12 Months): $3,235,137.92
Insider Selling (Last 12 Months): $342,214.59

Centessa Pharmaceuticals Insider Trading History Chart

This chart shows the insider buying and selling history at Centessa Pharmaceuticals by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Centessa Pharmaceuticals Share Price & Price History

Current Price: $4.35
Price Change: Price Decrease of -0.4 (-8.42%)
As of 08/11/2022 02:19 PM ET

This chart shows the closing price history over time for CNTA up to the past year.

Skip Chart and Table DataPrice Data in Insider Trading History Table
Days: 30 | 90 | 365
A One Stop Shop for Everything Futures Trading
Whether you're looking to learn the basics of futures or are a seasoned vet looking to hone your trading skills, our Technical Analysis Guide has everything you need to succeed in today's futures markets!
Download your FREE Technical Analysis Trading Guide Today.

Centessa Pharmaceuticals Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
8/1/2022Antoine YverEVPSell10,423$4.45$46,382.35800,174View SEC Filing Icon  
7/18/2022Antoine YverEVPSell20,000$4.87$97,400.00810,597View SEC Filing Icon  
7/1/2022Antoine YverEVPSell9,100$5.03$45,773.00730,597View SEC Filing Icon  
6/24/2022Saurabh SahaCEOBuy10,000$4.63$46,300.0038,000View SEC Filing Icon  
6/17/2022Antoine YverEVPSell9,200$4.68$43,056.00739,697View SEC Filing Icon  
5/17/2022Antoine YverEVPSell20,222$5.42$109,603.24813,675View SEC Filing Icon  
2/2/2022Saurabh SahaCEOBuy5,000$9.74$48,700.00View SEC Filing Icon  
1/28/2022David J. GraingerInsiderBuy27,500$9.05$248,875.00View SEC Filing Icon  
12/2/2021Medicxi Ventures Management (JMajor ShareholderBuy34,326$12.82$440,059.32View SEC Filing Icon  
12/1/2021Francesco De RubertisDirectorBuy60,304$12.62$761,036.48View SEC Filing Icon  
11/30/2021Medicxi Ventures Management (JMajor ShareholderBuy36,847$11.62$428,162.14View SEC Filing Icon  
11/29/2021Francesco De RubertisDirectorBuy56,706$11.70$663,460.20View SEC Filing Icon  
11/26/2021Francesco De RubertisDirectorBuy11,817$11.34$134,004.78View SEC Filing Icon  
11/18/2021Aaron KantoffDirectorBuy10,000$11.98$119,800.00View SEC Filing Icon  
11/16/2021Saurabh SahaCEOBuy23,000$12.28$282,440.00View SEC Filing Icon  
11/16/2021Tia L. BushInsiderBuy5,000$12.46$62,300.00View SEC Filing Icon  
See Full Table
The Safest Option in Trades!
If you’re new to trading, then you’ve probably heard the wrong thing about options—that they’re risky, unpredictable, or difficult.

And it couldn’t be more wrong! With the Hughes Optioneering Strategy, you’ll soon learn that the safest option for new accounts is options themselves!
Click here now!

SEC Filings (Institutional Ownership Changes) for Centessa Pharmaceuticals (NASDAQ:CNTA)

95.72% of Centessa Pharmaceuticals stock is owned by institutions. Institutional ownership can be a sign of analyst confidence in the fundamentals of the stock.

Institutional Buying and Selling by Quarter

This chart shows the instiutional buying and selling at CNTA by year and by quarter.

Skip Institutional Buying and Selling Chart and Table DataRead Chart Data in Institutional Trading History Table

Centessa Pharmaceuticals Institutional Trading History

Reporting DateHedge FundShares HeldMarket Value% of PortfolioQuarterly Change in SharesOwnership in CompanyDetails
8/11/2022Alps Advisors Inc.55,785$0.27M0.0%N/A0.059%Search for SEC Filing on Google Icon
8/11/2022JPMorgan Chase & Co.178,414$0.87M0.0%+3,683.2%0.190%Search for SEC Filing on Google Icon
8/4/2022TD Asset Management Inc.82,055$0.40M0.0%+146.8%0.087%Search for SEC Filing on Google Icon
7/26/2022Mirae Asset Global Investments Co. Ltd.57,342$0.70M0.0%N/A0.061%Search for SEC Filing on Google Icon
6/7/2022Bank of America Corp DE44,177$0.40M0.0%-44.3%0.047%Search for SEC Filing on Google Icon
5/18/2022Golden State Equity Partners15,970$0.14M0.1%+15.1%0.017%Search for SEC Filing on Google Icon
5/17/2022Ensign Peak Advisors Inc316,601$2.84M0.0%-7.8%0.337%Search for SEC Filing on Google Icon
5/16/2022Woodline Partners LP882,633$7.92M0.1%+10.2%0.939%Search for SEC Filing on Google Icon
5/16/2022Prelude Capital Management LLC11,400$0.10M0.0%N/A0.012%Search for SEC Filing on Google Icon
5/13/2022Affinity Asset Advisors LLC65,282$0.59M0.1%-84.4%0.069%Search for SEC Filing on Google Icon
5/13/2022Kynam Capital Management LP669,100$6M1.9%+179.9%0.712%Search for SEC Filing on Google Icon
5/12/2022BlackRock Inc.276,518$2.48M0.0%-3.7%0.294%Search for SEC Filing on Google Icon
5/4/2022OUP Management Co. LLC2,937,615$26.35M20.1%+25.4%3.124%Search for SEC Filing on Google Icon
2/19/2022Woodline Partners LP801,136$9.02M0.1%-9.3%0.891%Search for SEC Filing on Google Icon
2/15/2022Samsara BioCapital LLC1,459,693$16.44M3.2%-5.1%1.624%Search for SEC Filing on Google Icon
2/14/2022Virtus ETF Advisers LLC14,798$0.17M0.1%N/A0.016%Search for SEC Filing on Google Icon
2/14/2022Boxer Capital LLC1,251,137$14.09M0.5%-6.2%1.392%Search for SEC Filing on Google Icon
2/14/2022Point72 Asset Management L.P.1,097,908$12.36M0.0%+263.3%1.221%Search for SEC Filing on Google Icon
2/14/2022Deep Track Capital LP400,000$4.50M0.3%N/A0.445%Search for SEC Filing on Google Icon
2/14/2022Affinity Asset Advisors LLC419,144$4.72M1.7%+106.3%0.466%Search for SEC Filing on Google Icon
2/11/2022Ensign Peak Advisors Inc343,292$3.87M0.0%+19.9%0.382%Search for SEC Filing on Google Icon
2/9/2022Compagnie Lombard Odier SCmA5,820$66K0.0%+111.6%0.006%Search for SEC Filing on Google Icon
2/7/2022American Century Companies Inc.517,123$5.82M0.0%+39.7%0.575%Search for SEC Filing on Google Icon
2/3/2022OUP Management Co. LLC2,341,891$26.37M11.9%N/A2.605%Search for SEC Filing on Google Icon
2/3/2022Medicxi Ventures Management Jersey Ltd18,123,892$204.08M51.1%+1.1%20.160%Search for SEC Filing on Google Icon
11/16/2021Janus Henderson Group PLC5,607,302$91.36M0.0%-1.3%6.237%Search for SEC Filing on Google Icon
11/16/2021Brookfield Asset Management Inc.26,788$0.45M0.0%+45.6%0.030%Search for SEC Filing on Google Icon
11/16/2021Millennium Management LLC337,002$5.63M0.0%-38.6%0.375%Search for SEC Filing on Google Icon
11/16/2021Boxer Capital LLC1,334,227$22.28M0.8%+47.6%1.484%Search for SEC Filing on Google Icon
11/16/2021Citadel Advisors LLC349,548$5.84M0.0%-23.4%0.389%Search for SEC Filing on Google Icon
11/15/2021Point72 Asset Management L.P.302,200$5.05M0.0%+202.2%0.336%Search for SEC Filing on Google Icon
11/15/2021RA Capital Management L.P.3,577,094$59.74M0.8%+179.4%3.979%Search for SEC Filing on Google Icon
11/15/2021General Atlantic L.P.9,681,818$161.69M0.9%+545.5%10.770%Search for SEC Filing on Google Icon
11/15/2021Ensign Peak Advisors Inc286,404$4.78M0.0%-18.2%0.319%Search for SEC Filing on Google Icon
11/12/2021Affinity Asset Advisors LLC203,183$3.39M0.9%+203.5%0.226%Search for SEC Filing on Google Icon
11/12/2021Ghisallo Capital Management LLC15,000$0.25M0.0%-40.0%0.017%Search for SEC Filing on Google Icon
11/10/2021American Century Companies Inc.370,292$6.18M0.0%-0.3%0.412%Search for SEC Filing on Google Icon
11/9/2021Jennison Associates LLC296,456$4.95M0.0%-1.2%0.330%Search for SEC Filing on Google Icon
10/28/2021Compagnie Lombard Odier SCmA2,750$46K0.0%N/A0.003%Search for SEC Filing on Google Icon
8/25/2021Marshall Wace North America L.P.34,228$0.76M0.0%N/A0.038%Search for SEC Filing on Google Icon
8/18/2021Blackstone Inc40,000$0.89M0.0%N/A0.044%Search for SEC Filing on Google Icon
8/17/2021Woodline Partners LP822,518$18.27M0.3%N/A0.915%Search for SEC Filing on Google Icon
8/17/2021Samsara BioCapital LLC1,537,533$34.15M4.2%N/A1.710%Search for SEC Filing on Google Icon
8/17/2021Brookfield Asset Management Inc.18,404$0.41M0.0%N/A0.020%Search for SEC Filing on Google Icon
8/17/2021Logos Global Management LP939,545$20.87M1.8%N/A1.045%Search for SEC Filing on Google Icon
8/17/2021Millennium Management LLC548,452$12.18M0.0%N/A0.610%Search for SEC Filing on Google Icon
8/17/2021Price T Rowe Associates Inc. MD2,011,073$43.86M0.0%N/A2.237%Search for SEC Filing on Google Icon
8/17/2021BVF Inc. IL58,900$1.31M0.0%N/A0.066%Search for SEC Filing on Google Icon
8/17/2021Boxer Capital LLC904,227$20.08M0.7%N/A1.006%Search for SEC Filing on Google Icon
8/17/2021Caas Capital Management LP62,500$1.39M0.0%N/A0.070%Search for SEC Filing on Google Icon
8/17/2021Citadel Advisors LLC456,233$10.13M0.0%N/A0.507%Search for SEC Filing on Google Icon
8/16/2021Squarepoint Ops LLC37,771$0.84M0.0%N/A0.042%Search for SEC Filing on Google Icon
8/16/2021Point72 Asset Management L.P.100,000$2.22M0.0%N/A0.111%Search for SEC Filing on Google Icon
8/16/2021Blackstone Inc40,000$0.89M0.0%N/A0.044%Search for SEC Filing on Google Icon
8/16/2021RA Capital Management L.P.1,280,300$28.44M0.5%N/A1.424%Search for SEC Filing on Google Icon
8/16/2021Tudor Investment Corp Et Al43,079$0.96M0.0%N/A0.048%Search for SEC Filing on Google Icon
8/16/2021Avoro Capital Advisors LLC500,000$11.11M0.2%N/A0.556%Search for SEC Filing on Google Icon
8/13/2021General Atlantic L.P.1,500,000$33.32M0.2%N/A1.669%Search for SEC Filing on Google Icon
8/13/2021VR Adviser LLC1,127,272$25.04M3.0%N/A1.254%Search for SEC Filing on Google Icon
8/13/2021Northern Trust Corp18,400$0.41M0.0%N/A0.020%Search for SEC Filing on Google Icon
8/13/2021Affinity Asset Advisors LLC66,957$1.49M0.5%N/A0.074%Search for SEC Filing on Google Icon
8/13/2021Franklin Resources Inc.922,700$20.49M0.0%N/A1.026%Search for SEC Filing on Google Icon
8/13/2021Ensign Peak Advisors Inc350,000$7.77M0.0%N/A0.389%Search for SEC Filing on Google Icon
8/13/2021Geode Capital Management LLC9,513$0.21M0.0%N/A0.011%Search for SEC Filing on Google Icon
8/13/2021FMR LLC790,000$17.55M0.0%N/A0.879%Search for SEC Filing on Google Icon
8/12/2021Vida Ventures Advisors LLC3,931,818$87.33M21.9%N/A4.374%Search for SEC Filing on Google Icon
8/12/2021State of Wisconsin Investment Board80,381$1.79M0.0%N/A0.089%Search for SEC Filing on Google Icon
8/12/2021JPMorgan Chase & Co.2,090$47K0.0%N/A0.002%Search for SEC Filing on Google Icon
8/12/2021Jennison Associates LLC300,000$6.66M0.0%N/A0.334%Search for SEC Filing on Google Icon
8/12/2021Monashee Investment Management LLC130,000$2.89M0.3%N/A0.145%Search for SEC Filing on Google Icon
8/5/2021American Century Companies Inc.371,504$8.25M0.0%N/A0.413%Search for SEC Filing on Google Icon
Data available starting January 2016

See Full Table
Centessa Pharmaceuticals logo
Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; and SerpinPC, an activated protein C inhibitor, which is in Phase IIa clinical development for the treatment of hemophilia A and B. The company also has emerging pipeline products under clinical proof of concept stage comprising LB101, a PD-L1xCD47 LockBody, as well as LB201, a PD-L1xCD3 LockBody, which are designed to selectively drive potent CD47 and CD3 effector function activity while avoiding systemic toxicity; ZF874, a small molecule pharmacological chaperone folding corrector of the Z variant of alpha-1-antitrypsin in Phase I clinical development for the treatment of alpha-1-antitrypsin deficiency; MGX292, a recombinant modified BMP9 replacement protein designed to overcome the deficiency in BMP9 signaling in Pulmonary Arterial Hypertension; and OX2R Agonists that are oral and intranasal selective orexin receptor 2 agonists designed to leverage structural insights and to directly target the underlying pathophysiology of orexin neuron loss in Narcolepsy Type 1. In addition, the company has exploratory pipeline products under clinical proof of concept stage containing CBS001, an anti-LIGHT antibody, which preferentially binds the inflammatory membrane form of LIGHT in inflammatory/fibrotic diseases; and CBS004, a humanized mAb specific to BDCA2, expressed exclusively on plasmacytoid dendritic cells in systemic sclerosis, systemic lupus erythematosus, and other autoimmune diseases. Centessa Pharmaceuticals plc was incorporated in 2020 and is based in Altrincham, the United Kingdom.
Read More on Centessa Pharmaceuticals

Today's Range

Now: $4.35
Low: $4.27
High: $4.81

50 Day Range

MA: $4.65
Low: $3.18
High: $5.91

52 Week Range

Now: $4.35
Low: $2.88
High: $25.98

Volume

591 shs

Average Volume

136,702 shs

Market Capitalization

$409.07 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.27

Who are the company insiders with the largest holdings of Centessa Pharmaceuticals?

Centessa Pharmaceuticals' top insider shareholders include:
  1. Antoine Yver (EVP)
  2. Saurabh Saha (CEO)
  3. (Bermuda) Ltd Gap (Major Shareholder)
  4. Aaron Kantoff (Director)
  5. David J Grainger (Insider)
  6. Medicxi Ventures Management (J (Major Shareholder)
  7. Rubertis Francesco De (Director)
  8. Tia L Bush (Insider)
Learn More about top insider investors at Centessa Pharmaceuticals.

Who are the major institutional investors of Centessa Pharmaceuticals?

Centessa Pharmaceuticals' top institutional investors include:
  1. JPMorgan Chase & Co. — 0.19%
  2. TD Asset Management Inc. — 0.09%
  3. Mirae Asset Global Investments Co. Ltd. — 0.06%
  4. Alps Advisors Inc. — 0.06%
Learn More about top institutional investors of Centessa Pharmaceuticals stock.

Which institutional investors are buying Centessa Pharmaceuticals stock?

During the previous quarter, CNTA stock was purchased by institutional investors including:
  1. JPMorgan Chase & Co.
  2. Mirae Asset Global Investments Co. Ltd.
  3. Alps Advisors Inc.
  4. TD Asset Management Inc.
During the previous year, these company insiders have bought Centessa Pharmaceuticals stock:
  1. Antoine Yver (EVP)
  2. Saurabh Saha (CEO)
  3. (Bermuda) Ltd Gap (Major Shareholder)
  4. Aaron Kantoff (Director)
  5. David J Grainger (Insider)
  6. Medicxi Ventures Management (J (Major Shareholder)
  7. Rubertis Francesco De (Director)
Learn More investors buying Centessa Pharmaceuticals stock.
Here's Bill Bonner's "4th and Final Prediction"
One of America's most successful entrepreneurs goes public with "4th and Final Prediction." His first three all came true—will this one too?
Click here for details...